Redeye updates its estimates and valuation following Mentice’s Q4 2023 report. The quarter featured rather anaemic sales growth and profitability, though its order intake and M&A bode well for continued profitable growth. Mentice opportunistically acquired all substantial assets from competitor Biomodex, complementing its existing product offering. We judge the company’s long-term prospects remain essentially unchanged.